Independent Mechanistic Inhibition of Cdc25 Phosphatases by a Natural Product Cauli bugulone.

Marni Brisson, Caleb Foster, Peter Wipf, Beomjun Joo, Robert J. Tomko Jr., Theresa Nguyen and John S. Lazo

Departments of Pharmacology (M.B., T.N., C.F., R.J.T, J.S.L.) and Chemistry (P.W., B.J.), the Center for Chemical Methodologies and Library Development (P.W., B.J.) and the Drug Discovery Institute (M.B., C.F., P.W., R.J.T, J.S.L), University of Pittsburgh, Pittsburgh, PA 15260
MOL 28589

Running title: Inhibition of Cdc25 by caulibugulones

Corresponding author: John S. Lazo; Drug Discovery Institute, University of Pittsburgh, BST3, Suite 10040, 3501 Fifth Ave., Pittsburgh, PA 15260-0001; Fax: 412-618-9009;
Email: lazo@pitt.edu

Number of text pages: 32
Number of Tables: 1
Number of Figures: 8
Number of References: 35
Number of words in Abstract: 172
Number of words in Introduction: 557
Number of words in Discussion: 939

Abbreviations: Cdk, cyclin dependent kinases; DA3003-1, 6-chloro-7-(2-morpholin-4-yl-ethylamino)-quinoline-5,8-dione; Cauli, caulibugulone; DCF, 2',7'-dichlorodihydrofluorescein; DTT, dithiolthreitol; H2DCFDA, 2',7'-dichlorodihydrofluorescein diacetate; IC50, concentration of compound required for 50% inhibition; JUN1111, 7-(2-morpholin-4-yl-ethylamino)-quinoline-5,8-dione; DMEM, Dulbecco’s Minimal Essential Medium; FBS, fetal bovine serum; NAC, N-acetyl-L-cysteine; OMFP, O-methyl fluorescein phosphate; PBS, phosphate buffered saline; PI, propidium iodide; ROS, reactive oxygen species; tet, tetracycline; UV, ultraviolet irradiation; 5169131, 3-benzoyl-naphtho[1,2-b]furan-4,5-dione; STAT3, signal transducer and activator of transcription 3; Rb, retinoblastoma protein.
ABSTRACT

Caulibugulones are novel but poorly characterized cytotoxic isoquinoline quinones and iminoquinones identified in extracts from the marine bryozoan *Caulibugula intermis*. We now report that the caulibugulones are selective *in vitro* inhibitors of the Cdc25 family of cell cycle controlling protein phosphatases as compared with either human VHR or PTP1B phosphatases. The *in vitro* inhibition of Cdc25B by caulibugulone A was irreversible and attenuated by reducing agents or catalase, consistent with direct oxidation of the enzyme by reactive oxygen species. Mechanistically, caulibugulone A directly inhibited cellular Cdc25B activity, generated intracellular reactive oxygen species and arrested cells in both G1 and G2/M phases of the cell cycle. Caulibugulone A also caused the selective degradation of Cdc25A protein by a process that was independent of reactive oxygen species production, proteasome activity, and the Chk1 signaling pathway. Instead, caulibugulone A stimulated the phosphorylation and subsequent activation of p38 stress kinase leading to Cdc25A degradation. Thus, caulibugulone inhibition of cellular Cdc25A and B phosphatases occurred through at least two different mechanisms, leading to pronounced cell cycle arrest.
INTRODUCTION

Caulibugulones A-F are novel secondary metabolites originally extracted from the marine bryozoan Caulibugula intermis (Milanowski et al., 2004). The isoquinoline quinones, caulibugulones A, B and C, and the isoquinoline iminoquinones, caulibugulones E and F, caused growth arrest of murine IC-2\textsuperscript{WT} cells with IC\textsubscript{50} values ranging from 0.03 – 1.67 µg/ml (Milanowski et al., 2004). We previously reported the total syntheses for these naturally occurring compounds and their ability to inhibit Cdc25B \textit{in vitro} (Alagille et al., 2004; Wipf et al., 2004). Since the mechanisms responsible for caulibugulone-mediated growth arrest were not defined, the goal of this study was to further characterize the mode of action of these natural products.

Much of our work has been focused on identifying small molecule inhibitors of Cdc25 phosphatases because of their critical role in regulating the cell cycle controlling cyclin dependent kinases (Cdk) (Lyon et al., 2002). All three Cdc25 phosphatases permit G\textsubscript{2}/M transition by dephosphorylating and activating the Cdk1/cyclin B complex. Cdc25A also induces transition from G\textsubscript{1} to S phase by dephosphorylation of Cdk2/cyclin E and Cdk2/cyclin A (Blomberg and Hoffmann, 1999; Hoffmann et al., 1994) and both Cdc25B and Cdc25C have been implicated in initiating entry into S phase (Garner-Hamrick and Fisher, 1998; Turowski et al., 2003). Cdc25A and Cdc25B but not Cdc25C are overexpressed in human cancer cells and appear to contribute to oncogenesis (Kristjansdottir and Rudolph, 2004).
Endogenous regulation of Cdc25 phosphatases is also a central feature of mammalian cell cycle checkpoints. Clinically used anticancer agents, such as topoisomerase I inhibitors, topoisomerase II inhibitors, and DNA damaging agents (UV, IR), decrease Cdc25A protein levels leading to cell cycle arrest (Agner et al., 2005). The resulting proteosomal degradation of Cdc25A is accomplished by activation of the ATM/ATR-Chk1/Chk2 cascade, phosphorylation of Cdc25A on key serine residues followed by ubiquitination and degradation of Cdc25A. Phosphorylation of all three of the Cdc25 phosphatases is also important for creating 14-3-3 binding sites in order to sequester the phosphatases away from their substrates and induce cell cycle arrest (Boutros et al., 2006).

We and others have observed that the most potent small molecule inhibitors of the Cdc25 phosphatases are frequently quinone-derived compounds (Boutros et al., 2006; Brisson et al., 2004; Brisson et al., 2005; Kristjansdottir and Rudolph, 2004; Lazo et al., 2001; Lazo et al., 2002; Lyon et al., 2002). We previously hypothesized (Brisson et al., 2005) that quinoid inhibitors could disrupt Cdc25B phosphatase activity by oxidation of the catalytically essential cysteine residue in the enzyme’s active site through production of reactive oxygen species. Therefore, in the current study we analyzed this mode of action for the newly synthesized caulibugulone quinones. Caulibugulones A-E were previously shown to be in vitro inhibitors of Cdc25B with IC$_{50}$ values ranging from 2.7 – 32.5 µM, demonstrating specificity for Cdc25B over two other known phosphatases: VHR and PTP1B (Wipf et al., 2004). We now report that caulibugulone A inhibited all human Cdc25 isoforms, generated a modest level of reactive oxygen species in cells, irreversibly inhibited Cdc25B, and caused G$_1$ and G$_2$/M phase cell cycle arrest. Surprisingly,
caulibugulone A inhibited Cdc25A by a completely separate mechanism, namely Cdc25A degradation, which relied on the p38 stress kinase but was independent of reactive oxygen species, proteosome activity, and the Chk1 signaling pathway. Depletion of Cdc25A was observed with other quinone Cdc25 inhibitors, suggesting it was a general and possibly important pharmacological phenomenon.
MATERIALS AND METHODS

Chemicals. The syntheses of caulibugulones A-E, DA30031 and JUN1111 were previously reported (Brisson et al., 2005; Wipf et al., 2004). 5169131 was purchased from Chembridge Research Laboratories, Inc., San Diego, California. All other chemicals were purchased from Sigma Aldrich, St. Louis, MO, unless otherwise noted.

In vitro enzyme assays. Epitope-tagged His6Cdc25A1, His6Cdc25B2, and GST-Cdc25C1 were expressed in E. coli and purified by Ni-NTA (His6) or glutathione Sepharose resin (GST) as previously described (Lazo et al., 2001). Human recombinant VHR and PTP1B were purchased from BIOMOL (Plymouth Meeting, PA). Enzyme activities in the absence and presence of inhibitors were measured using the artificial substrate O-methyl fluorescein phosphate (OMFP) at concentrations equal to the K\textsubscript{m} of each enzyme and at the optimal pH for individual enzyme activity in a 96-well microtiter plate assay based on previously described methods (Lazo et al., 2001). Fluorescence emission from the product was measured after a 20 min (VHR, PTP1B) or 60 min (Cdc25) incubation period at ambient temperature with a multiwell plate reader (Cytofluor II; Applied Biosystems, Foster City, CA; excitation filter, 485 nm/20 nm bandwidth; emission filter, 530 nm/30 nm bandwidth). IC\textsubscript{50} concentrations were determined using Prism 3.0 (GraphPad Software, Inc., San Diego, CA). For reversibility studies with inhibitors, we used a protocol similar to a dilution method described previously (Sohn et al., 2003). Cdc25B2 full-length enzyme (60 mM Tris, 2 mM EDTA, 150 mM NaCl, pH 8.0) was preincubated with ~3x the IC\textsubscript{50} of caulibugulone A (20 µM) for 0, 5 or 20 min at room temperature. Separately, the enzyme was also incubated with the DMSO vehicle. After
preincubation, the reaction was diluted > 10-fold to determine remaining enzyme activity
by the above-mentioned phosphatase assay using OMFP and results were compared with
enzyme incubated with the DMSO vehicle.

Cell cycle analysis and measurement of cellular ROS by flow cytometry. tsFT210
cell synchronization and flow cytometry assays were performed as previously described
(Osada et al., 1997) using a FACSCalibur flow cytometer (BD Pharmingen). HeLa cells
(1x10^6), cultured in Dulbecco’s Minimal Essential Medium (DMEM) containing 10%
fetal bovine serum (FBS), were trypsinized, resuspended in phosphate buffer saline
(PBS) and preloaded with 2',7'-dichlorodihydrofluorescein diacetate (H_2DCF) dye
(Molecular Probes, Eugene, OR). Cells were washed in PBS and resuspended in PBS
buffer containing 3 μM propidium iodide (PI). Cells were then treated for 10 min with
DMSO, 1 mM H_2O_2, caulibugulone A or JUN1111. DCF (2',7'-
dichlorodihydrofluorescein) and propidium iodide (PI) fluorescence were measured by
flow cytometry and data were analyzed using ModFit LT cell-cycle analysis software
(Verity Software House, Topsham, ME).

Direct inhibition of Cdc25B in U2OS cells. Previously described (Bugler et al., 2006;
Theis-Febvre et al., 2003) U2OS cells overexpressing HA-Cdc25B_3 under the
tetracycline (tet)-repressible promoter (a generous gift from Prof. Bernard Ducommun)
were maintained in DMEM constituted with 10% FBS, G418 (100 μg/ml), 1% penicillin–
streptomycin and 2 μg/ml tet. Cells were plated for 23 h with tet to suppress ectopic
Cdc25B expression and without tet to stimulate ectopic Cdc25B expression. Cells were
then treated with 40 μM etoposide for 1 h followed by addition of 200 ng/ml nocodazole alone or in the presence of caulibugulone A (1–30 μM) for 23 h. Cells were harvested in cold lysis buffer (50 mM Tris HCl, pH 7.5, containing 250 mM NaCl, 5 mM EDTA, and 0.1% Triton X-100) supplemented with various protease and phosphatase inhibitors. Phosphorylated Histone H3 (Ser10), a well established marker of mitotic arrest (Hendzel et al., 1997), was detected by Western blot using a rabbit polyclonal antibody from Millipore Corporation (Billerica, MA).

**Treatment of HeLa cells and Western blotting.** HeLa cells were cultured in DMEM containing 10% FBS. Cells (0.5-1x10⁶) were plated in 10 cm dishes and treated with DMSO (vehicle) or with the following conditions: 1 – 1000 μM H₂O₂ for 2 h; 1 - 30 μM of quinone (caulibugulone A or E, JUN1111, DA3003-1 or 5169131) for 2 h; pretreatment with 20 mM N-acetyl-L-cysteine (NAC) for 2 h followed by addition of caulibugulone A for 2 h; pretreatment with 1, 10 or 20 μM of the p38 inhibitor SB203580 (Calbiochem, San Diego, CA) for 1 h followed by addition of caulibugulone A for 2 h; or pretreatment with 5 μM MG132 for 15 h followed by 30 μM caulibugulone A for 2 h. In some studies, cells were exposed to UV irradiation (60 J/m²) with or without MG132 or SB203580 pretreatment. Cycloheximide (25 μg/ml) was added to cells in the presence of DMSO vehicle or 30 μM caulibugulone A for 0 – 30 min for Cdc25A half-life determination. After treatments, cells were lysed in cold lysis buffer as stated above. Cdc25 phosphatase protein levels were detected by Western blotting with the following antibodies: mouse monoclonal anti-Cdc25A (F6, Santa Cruz Biotech., Santa Cruz, California), mouse monoclonal anti-Cdc25B (BD Transduction, San Jose, CA), and
mouse monoclonal anti-Cdc25C (H-6, Santa Cruz Biotech.). Phospho-Chk1 (Ser345) and phospho-Chk2 (Thr68) antibodies were purchased from Cell Signaling (Danvers, MA). Phospho-p38 (Thr180/Tyr182) and total p38 antibodies were purchased from Cell Signaling.
RESULTS

Crystallographic data (Reynolds et al., 1999) and molecular modeling studies (Lavecchia et al., 2006) suggest that the active sites in the Cdc25 family members are sufficiently different, suggesting that selectivity among catalytic inhibitors of Cdc25 phosphatases may be possible. Thus, we expanded our previous investigation of caulibugulone inhibition of Cdc25B (Wipf et al., 2004) to examine the selectivity of these compounds against all three human Cdc25 phosphatases. Using identical reaction conditions, we found caulibugulone A-E inhibited recombinant human Cdc25 A, B and C phosphatase activity in vitro with IC$_{50}$ values ranging from 1.51 – 32.5 µM, with caulibugulone E being the least potent (Table 1). Consistent with molecular modeling predictions, all of the caulibugulones, like some of the para-quinones previously studied (Brisson et al., 2005), showed a modest (2-3 fold) preference for Cdc25A versus Cdc25B or Cdc25C (Table 1). Caulibugulone A, D, and E were specific for the Cdc25 phosphatase family, as compared to VHR and PTP1B where the IC$_{50}$ values exceeded 1 mM, whereas caulibugulones B and C were less specific. We focused our attention on caulibugulone A because of its potency, its higher specificity as compared to caulibugulones B and C, and the relative simplicity of its chemical structure.

Our previous studies (Brisson et al., 2005) revealed that quinone inhibitors of Cdc25 phosphatases induce irreversible oxidation of the catalytic cysteine of Cdc25B through the production of ROS. Consistent with this hypothesis, the degree of inhibition by caulibugulone A was reduced with increasing concentrations of DTT, respectively. Addition of catalase (80 U/ml) also increased the IC$_{50}$ of caulibugulone A against
Cdc25B by 16-fold, suggesting that H2O2 may be involved in the oxidation of Cdc25B (data not shown). Because these data suggested that caulibugulone A might oxidize Cdc25B, we investigated the ability of caulibugulone A to produce ROS in HeLa cells. As seen in Figure 1A, caulibugulone A (30 µM) caused a small increase in DCF fluorescence in HeLa cells that was less than that seen with H2O2 (1 mM) or with JUN1111 (10 µM), a quinone inhibitor of Cdc25B previously shown to produce ROS (Brisson et al., 2005). Irreversible inhibition of Cdc25B in vitro was also seen when the enzyme was pretreated with caulibugulone A for up to 20 min using a previously described dilution method (Sohn et al., 2003) (Figure 1B). These data suggest that caulibugulone A emulated other quinone inhibitors by irreversibly inhibiting Cdc25B through the production of ROS.

To determine if caulibugulone A inhibited cellular Cdc25B, we exploited a U2OS cell line that conditionally overexpresses hemagglutinin (HA) and His6-tagged Cdc25B3 under the control of the tet-promoter as compared to the nearly undetectable endogenous Cdc25B levels seen in non-transfected U2OS cells as previously described (Bugler et al., 2006) (Figure 2A). Removal of tet resulted in robust expression of Cdc25B as revealed by the epitope tagged protein (Figure 2A). Treatment of cycling cells with nocodazole, a potent mitotic blocker, resulted in prominent phosphorylation of Ser10 on Histone H3, a well established marker for mitotic cells (Hendzel et al., 1997) (Figure 2B). The topoisomerase II inhibitor etoposide activates a G2 checkpoint, preventing cells from progressing into mitosis in the absence or presence of nocodazole. When overexpression of Cdc25B expression was blocked (+ tet) and cells were treated with etoposide and
nocodazole, the etoposide prevented continuation into mitosis, causing arrest at the $G_2$ phase of the cell cycle and absence of the phospho-Histone H3 signal (Figure 2B). In contrast, when tet-free U2OS cells overexpressing Cdc25B were treated with both etoposide and nocodazole, they bypassed the etoposide-mediated $G_2$ checkpoint and exhibited a high phospho-Histone H3 signal, indicative of mitotic trapping by nocodazole. When tet-free U2OS cells overexpressing Cdc25B were treated with etoposide, nocodazole and caulibugulone A, we observed a concentration-dependent caulibugulone A elimination of Histone H3 phosphorylation, consistent with Cdc25B inhibition, thus allowing for etoposide-mediated $G_2$ arrest (Figure 2B). Furthermore, exposure of synchronized tsFT210 cells to 1, 10 and 30 $\mu$M caulibugulone A induced a profound $G_2/M$ cell cycle arrest (Figure 3) in agreement with the direct inhibition of Cdc25 phosphatases. Exposure to as little as 1 $\mu$M caulibugulone A reduced progression through mitosis (Figure 3E). Caulibugulone A treatment of tsFT210 cells that were released from mitotic arrest resulted in a $G_1$ cell cycle arrest (Figure 4), also consistent with Cdc25 phosphatase inhibition.

We next investigated the fate of Cdc25B protein levels after caulibugulone A treatment since growth factors and some DNA damaging agents have been shown to increase Cdc25B (Oguri et al., 2004; Oguri et al., 2003). After treatment of HeLa cells with caulibugulone A, Cdc25B protein levels remained largely unaltered (Figure 5A). The slight decrease in Cdc25B levels seen with 30 $\mu$M caulibugulone A was not reproducible in subsequent experiments. In contrast, there was a reproducible complete loss of Cdc25A with 30 $\mu$M caulibugulone A as well as a mild decrease in Cdc25C protein
levels. Interestingly, addition of the iminoquinone, caulibugulone E, had no effect on Cdc25 phosphatase protein levels. The loss of Cdc25A was also observed in MDA-MB-231 and MCF7 human breast adenocarcinoma cells (Figure 5B). Caulibugulone A at 30 and 10 µM decreased the levels of Cdc25A in MDA-MB-231 cells below the DMSO vehicle control while the same concentrations completely eliminated Cdc25A levels in MCF7 cells. These results were reminiscent of decreased Cdc25A levels that we observed with the napthoquinone NSC 95397 in PC-3 human prostate cancer cells (Nemoto et al., 2004). Therefore, we tested three other previously described quinone Cdc25 phosphatase inhibitors, DA30003-1, JUN1111 and 5169131, at concentrations known to induce cell cycle arrest (Brisson et al., 2004; Brisson et al., 2005), for their ability to decrease endogenous Cdc25A protein levels. All three of these inhibitors depleted Cdc25A protein levels (Figure 5C), suggesting that the depletion of Cdc25A was a somewhat general characteristic of other known quinone inhibitors of the Cdc25 phosphatases.

Recent evidence suggests that H\textsubscript{2}O\textsubscript{2} could decrease Cdc25A transcription through formation of a STAT3 and Rb repressor complex at the Cdc25A promoter, leading to a reduction in Cdc25A (Barre et al., 2005). Because caulibugulone A produced a modest amount of cellular ROS and catalase blocked caulibugulone inhibition of Cdc25B \textit{in vitro}, we tested a possible role for H\textsubscript{2}O\textsubscript{2} in caulibugulone-mediated reduction of Cdc25A protein levels. Though addition of H\textsubscript{2}O\textsubscript{2} to Rb positive, HCT116 colon carcinoma cells caused a concentration-dependent loss in Cdc25A protein consistent with previous studies (Barre et al., 2005), this loss of Cdc25A protein was also observed in HeLa cells.
where Rb protein levels are decreased and the Rb pathway is inactivated due to overexpression of the human papillomavirus (HPV) E7 (Goodwin and DiMaio, 2000) (Figure 6A). Pretreatment of HeLa cells with the antioxidant N-acetyl-L-cysteine (NAC) prevented the H$_2$O$_2$-mediated loss of Cdc25A (Figure 6B). In contrast, pretreatment with the same concentration of NAC did not alter the caulibugulone-mediated reduction in Cdc25A (Figure 6C). Thus, the loss of Cdc25A after caulibugulone A treatment appeared to be independent of H$_2$O$_2$ production.

Constitutive Cdc25A protein degradation is believed to occur through a ubiquitin-proteasome mediated pathway that is accelerated by DNA damage via the ATM/Chk1 or ATR/Chk2 signaling cascade (reviewed in Busino et al., 2004). To determine if the loss of endogenous Cdc25A was due to protein degradation rather than transcriptional or translational regulation, we treated cells with cycloheximide from 0-30 min to halt protein synthesis in the presence or absence of caulibugulone A (Figure 7A). The half-life of Cdc25A in the presence of DMSO was approximately 20 min while the degradation of Cdc25A was greatly accelerated in the presence of caulibugulone A with a half-life of approximately 5 min, indicating that caulibugulone A enhanced Cdc25A protein degradation. However, Cdc25A degradation by caulibugulone A was not mediated by Chk1 or Chk2 pathways. Exposure of HeLa cells to UV resulted in Chk1 activation as revealed by Ser345 phosphorylation (Figure 7B). In contrast, neither caulibugulone A nor caulibugulone E caused phosphorylation of Chk1. We did observe phosphorylation of Chk2 (Thr68) after addition of caulibugulone A (10 or 30 µM) or caulibugulone E (30 µM) (Figure 7B) but neither 10 µM caulibugulone A nor 30 µM caulibugulone E.
caulibugulone E reduced Cdc25A levels (Figure 5A). Therefore, we believe the activation of phospho-Chk2 by caulibugulones A and E did not correlate with the changes observed in Cdc25A protein levels.

We previously observed that the proteasome had an important role in degradation of Cdc25A after treatment of cells with the napthoquinone NSC 95397 (Nemoto et al., 2004). Therefore, we investigated the functional importance of proteasome activity for the degradation seen with caulibugulone A. When HeLa cells were pretreated with the proteasome inhibitor MG132 (5 µM) for 15 h, constitutive Cdc25A turnover was blocked, as evidenced by an increase in the Cdc25A protein levels over the DMSO vehicle control (Figure 7C). The Cdc25A degradation induced by UV irradiation was also blocked by pretreatment with MG132. When we pretreated cells under the same conditions with MG132 and then added caulibugulone A for 2 h, caulibugulone A was still capable of degrading Cdc25A to levels well below that seen with MG132 alone (Figure 7C). These data indicated that the decrease in Cdc25A protein levels seen with caulibugulone A treatment was unlikely to be mediated by a proteasome-dependent mechanism.

Activation of the p38 signaling pathway by UV irradiation and other stressors has been implicated in the regulation of Cdc25 phosphatase activity (Boutros et al., 2006). Therefore, we examined cells treated with caulibugulone A for p38 activation using a phospho-specific antibody detecting dual phosphorylation at Thr180/Tyr182 on p38 (Figure 8A). Significant p38 activation was detected in cells treated with caulibugulone
A as well as with other quinone inhibitors of Cdc25 phosphatases, namely DA3003-1 and JUN1111. No changes in total p38 protein levels were noted. Upon preincubation with the selective p38 kinase inhibitor SB202190, the caulibugulone-mediated degradation of Cdc25A was blocked in a concentration-dependent manner (Figure 8B). In contrast, SB202190 did not prevent the UV-induced decrease in Cdc25A caused by DNA damage signaling pathways (Figure 8B). These results suggest that Cdc25A degradation induced by caulibugulone A was regulated through an alternative p38 kinase pathway, which is distinct from pathways involved in UV irradiation.
DISCUSSION

The caulibugulone natural products represent a unique class of cytotoxic marine-derived compounds with an unknown mechanism of action (Milanowski et al., 2004). The specificity of the caulibugulones for inhibition of Cdc25 phosphatases (Table 1) stimulated interest in examining the mechanism responsible for mammalian growth inhibition. Recent evidence suggested that at least some para-quinones act as inhibitors of the Cdc25B phosphatase in part by oxidizing and inactivating the catalytic cysteine of the enzyme through redox cycling and production of ROS (Brisson et al., 2005). Similar to several other quinone-based Cdc25 inhibitors, caulibugulone A produced ROS in cells (Figure 1) and induced irreversible Cdc25B inhibition that was sensitive to catalase. These data support the hypothesis that redox cycling could be one mechanism of caulibugulone A inhibition of Cdc25B.

A common response to some forms of cellular stress is a marked decrease in Cdc25A levels, resulting in cell cycle arrest. Caulibugulone A addition to HeLa cells at 30 µM caused a complete loss of Cdc25A through protein degradation (Figures 5 & 7A) that could mediate cell cycle arrest (Figures 3 & 4). Three other quinone inhibitors were also capable of degrading Cdc25A, consistent with our previous findings with NSC 95397 (Nemoto et al., 2004), suggesting that this is a fairly common phenomenon among known quinone inhibitors of Cdc25 phosphatases. In contrast to the Cdc25A decrease caused by H2O2 in HeLa cells, the Cdc25A loss by caulibugulone A was not prevented with NAC pretreatment (Figure 6), indicating that H2O2 was an unlikely mediator of the Cdc25A degradation induced by caulibugulone A.
The DNA damage checkpoint response induced by UV or ionizing irradiation is known to activate the ATM/ATR kinase signaling pathways which in turn phosphorylates Chk1 and Chk2 protein kinases, respectively (Boutros et al., 2006). Chk1 and Chk2 are responsible for regulating Cdc25 phosphatase activity to maintain cell cycle checkpoint integrity. Chk1 and Chk2 phosphorylate Cdc25A at Ser124/178/293, targeting the enzyme for ubiquitination and, ultimately, degradation by the proteasome, leading to cell cycle arrest (Busino et al., 2004). Caulibugulone A, however, did not induce Chk1 phosphorylation and activation (Figure 7B). Although modest Chk2 phosphorylation was seen with 10 and 30 µM caulibugulone A (Figure 7B), the phosphorylation of Chk2 after 10 µM caulibugulone A did not correlate with Cdc25A downregulation, since this concentration of caulibugulone A did not change Cdc25A levels (Figure 5A). In addition, 30 µM caulibugulone E caused prominent phosphorylation of Chk2 but had no effect on Cdc25A protein levels (Figure 5A & 7B). Further support that Cdc25A degradation was not mediated by Chk1 or Chk2 activation was evident by the inability of the proteasome inhibitor MG132 to prevent the degradation of Cdc25A in the presence of caulibugulone A (Figure 7C). This is contradictory to our previously published data that suggested a proteosome-dependent decrease in Cdc25A levels with NSC 95397 (Nemoto et al., 2004). In the previous experiment, PC-3 cells were pretreated for only 1 hr with 10 µM MG132, resulting in incomplete proteosome inhibition and a mild increase in endogenous Cdc25A levels. We believe that our interpretation of the previous data, suggesting a proteosome-dependent mechanism, would have been different under the more stringent conditions of the current study. Collectively, these data excluded the
ATM/ATR pathways as the primary participants responsible for the caulibugulone A-mediated degradation of Cdc25A, and suggested an unknown alternative proteosome-independent pathway of regulation.

The stress-activated protein kinase p38 has a recognized role in delaying entry into mitosis by controlling Cdc25 phosphatase activity when cells are stressed (Boutros et al., 2006). Under conditions of osmotic stress, p38 phosphorylates Cdc25A at Ser75, leading to degradation of Cdc25A (Goloudina et al., 2003). Khaled et al. also observed p38 phosphorylation of Cdc25A at Ser75 and Ser123 and subsequent degradation upon IL-3 and IL-7 cytokine withdrawal from lymphocytes, leading to G1/S arrest (Khaled et al., 2005). The p38 signaling pathway has also been implicated in instigating G2/M arrest after UV irradiation by phosphorylation of Cdc25B (Ser309/361) and Cdc25C (Ser216) (Bulavin et al., 2001). It is now believed that a downstream target of p38, MAPKAP kinase-2 is responsible for the phosphorylation of Cdc25B and C, leading to association with 14-3-3 and sequestration in the cytoplasm away from Cdk1/cyclin B (Manke et al., 2005). It is interesting, therefore, that caulibugulone A, which activated p38 (Figure 8A), caused a loss of Cdc25A with little or no loss of either Cdc25B or C (Figure 5A). The p38 specific inhibitor SB202190 partially restored Cdc25A levels in a concentration-dependent manner (Figure 8B) further implicating p38 kinase. This degradation of Cdc25A by p38 activation appears to be proteosome-independent (Figure 7C), indicating a new, previously unrecognized mechanism by which Cdc25A is degraded. Initial studies with p38 siRNA targeted to the α isoform were capable of decreasing p38 α levels by ~50% in cells treated with caulibugulone A; however, phosphorylated p38
levels were still present in α p38 siRNA transfected cells as compared to control siRNA upon caulibugulone A treatment, resulting in Cdc25A degradation (data not shown). Further studies are underway to determine whether decreasing the levels of the α isoform of p38 to >50% will be sufficient in significantly decreasing phosphorylated p38 or if other isoforms (β, γ or δ) of p38 need to be targeted. Due to the role of p38 in Cdc25B sequestration, it is also possible that this is yet another mechanism by which Cdc25B is regulated by caulibugulone A and other quinone inhibitors. These data provide added support for further studies of the potential antineoplastic actions of caulibugulone A as the p38 pathway has been shown to be activated by other clinically used chemotherapeutic agents (Hirose et al., 2004; Hirose et al., 2003; Mikhailov et al., 2004).
ACKNOWLEDGMENTS

We thank Professor Bernard Ducommun for generously providing us with the protocols and resources used in the experiments with the tetracycline-inducible U2OS cells expressing HA-Cdc25B3. We thank Pallavi Bansal for her assistance with aspects of these experiments.
REFERENCES


MOL 28589

FOOTNOTES

This work was supported in part by U. S. Public Health Service National Institutes of Health Grants CA78039, PA DOH-SAP#4100027294, and the Fiske Drug Discovery Fund.

To whom request for reprints should be addressed: Drug Discovery Institute, Department of Pharmacology, University of Pittsburgh, 3501 Fifth Ave., Biomedical Science Tower-3, Suite 10045, Pittsburgh, PA 15260; Email: laso@pitt.edu
FIGURE LEGENDS

Figure 1. Caulibugulone A is an irreversible inhibitor that produces ROS. Panel A. HeLa cells were preloaded with DCF dye and incubated for 10 min with DMSO vehicle, 1 mM H₂O₂, 10 µM JUN1111, or 30 µM caulibugulone A. ROS were detected by flow cytometry. Results are mean ± S.E.M. (n=3). Panel B. Cdc25B was preincubated with 20 µM caulibugulone A (3 x IC₅₀) for 0, 5, and 20 min and diluted >10 prior to an in vitro assay for phosphatase activity with the substrate, OMFP. Results are mean ± S.E.M. (n=4).

Figure 2. Caulibugulone A directly inhibits Cdc25B in cells. Panel A. HA-Cdc25B₃ expression was induced in U2OS cells by tetracycline removal from the medium for 23 h. Ectopic Cdc25B₃ expression was detected by Western blotting using an anti-HA tag antibody. Panel B. Cells either expressing or not expressing ectopic Cdc25B₃ were treated for 1 h with etoposide followed by 23 h with nocodazole (1µM) alone or nocodazole plus caulibugulone A at 1, 3, 10, or 30 µM. As a positive control, a subset of cells were treated with nocodazole alone. Cdc25B inhibition was assessed by examining phosphorylated Histone H3 (Ser10) levels in cell lysates using a phospho-specific antibody and Western blotting.

Figure 3. Caulibugulone A induces G₂/M cell cycle arrest. Murine tsFT210 cells were cultured at the permissive temperature of 32°C and then incubated for 17 h at 39.4°C to arrest cells in G₂/M. DMSO or drug was added to cells for an additional 6 h at 32°C.
MOL 28589

Panel A. Asynchronous control. Panel B. G2/M arrested cells after temperature shift for 17 h at 39.4°C. Panel C. DMSO treated cells. Panel D. Cells treated with 1 µM nocodazole (positive control). Panel E-G. Cells treated with 1-30 µM caulibugulone A. This was representative of two independent experiments.

Figure 4. Caulibugulone A induces G1 cell cycle arrest. tsFT210 cells were cultured at the permissive temperature of 32°C and then incubated for 17 h at 39.4°C to arrest cells in G2/M. Cells were then released for 4-6 h at 32°C to reinitiate cell cycle progression into G1. DMSO or drug was added for an additional 6 h at 32°C. Panel A. Asynchronous control. Panel B. G2/M arrested cells after temperature shift for 17 h at 39.4°C. Panel C. G1 arrested cells after temperature shift back to 32°C. Panel D. DMSO treated cells. Panel E. Cells treated with 50 µM roscovitine (positive control). Panel F-H. Cells treated with 1-30 µM caulibugulone A. This was representative of two independent experiments.

Figure 5. Endogenous Cdc25A protein levels decrease after treatment of HeLa cells with quinone inhibitors. Panel A. HeLa cells were treated with DMSO vehicle or 1, 10, or 30 µM caulibugulone A or E for 2 h prior to cell lysis and detection of Cdc25A, B or C by Western blot. Panel B. MDA-MB-231 and MCF7 cells were treated with DMSO vehicle or caulibugulone A (10 or 30 µM) for 2 h prior to cell lysis and detection of Cdc25A by Western blot. Panel C. HeLa cells were treated with DMSO vehicle, 10 µM DA3003-1, or 30 µM of JUN1111, 5169131 or caulibugulone A before cell lysis and detection of Cdc25A by Western blot. Blots are representative of at least 2 independent experiments.
Figure 6. H$_2$O$_2$ production by caulibugulone A does not contribute to Cdc25A degradation. Panel A. HeLa cells were treated with 1 – 1000 µM H$_2$O$_2$ for 2 h before detection of Cdc25A levels by Western blot. Panel B. Cdc25A levels after HeLa cells were pretreated with or without 20 mM NAC for 2 h followed by addition of DMSO vehicle or 1 mM H$_2$O$_2$ for 2 h. Panel C. HeLa cells were pretreated with or without 20 mM NAC for 2 h followed by a 2 h incubation with DMSO vehicle, 30 µM caulibugulone A alone or caulibugulone A with NAC pretreatment before detection of Cdc25A by Western blot. Blots are representative of at least 2 independent experiments.

Figure 7. Caulibugulone A instigates Cdc25A protein degradation via a proteasome-independent mechanism. Panel A. HeLa cells were exposed to cycloheximide (25 µg/ml) from 0 – 30 min in the presence of DMSO or caulibugulone A (30 µM) followed by cell lysis and detection of Cdc25A levels by Western blot. Quantification of the Western blot was performed by densitometry and band intensity for Cdc25A bands, as indicated below the panel, were normalized to tubulin and expressed as percentage of the corresponding 0 min control. Panel B. Phosphorylated Chk1 and Chk2 were detected in HeLa cells after treatment with 60 J/m² UV (positive control), 10 or 30 µM caulibugulones A or E for 2 h. Panel C. HeLa cells were pretreated for 15 h with DMSO vehicle control (lanes 1, 2 & 5) or 5 µM MG132 (lanes 3, 4 & 6). Cells were then treated for 2 h with DMSO vehicle (lane 1), 5 µM MG132 (lanes 3, 4 & 6), 30 µM caulibugulone A (lanes 2 & 4) or exposed to 60 J/m² UV (lanes 5 & 6) and incubated for 1 h. Cdc25A levels were assessed by Western blot. Blots are representative of at least 2 independent experiments.
Figure 8. Caulibugulone A degrades Cdc25A by activation of p38 kinase. Panel A. Phospho-p38 and total p38 protein levels in HeLa cells were detected after treatment with DMSO vehicle, anisomycin (positive control from Cell Signaling), DA3003-1 (10 µM), JUN1111 (30 µM) or caulibugulone A (30 µM) for 2 h. Panel B. Cells were pretreated with and without 1-20 µM SB202190 for 1 h followed by exposure to DMSO or 30 µM caulibugulone A before cell lysis and detection of Cdc25A levels by Western blot. UV treated cells at 60 J/m² alone or pretreated with the SB202190 inhibitor were used as controls. Blots are representative of at least 2 independent experiments.
Table 1. IC$_{50}$ values of caulibugulones for inhibition of recombinant human protein phosphatases. All values are µM concentrations and are the mean ± SEM of 3 or more independent determinations.

<table>
<thead>
<tr>
<th>Name</th>
<th>Structure</th>
<th>Cdc25A</th>
<th>Cdc25B$^a$</th>
<th>Cdc25C</th>
<th>VHR$^a$</th>
<th>PTP1B$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>caulibugulone A</td>
<td><img src="image1" alt="Structure" /></td>
<td>3.38 ± 0.62</td>
<td>6.74 ± 1.28</td>
<td>5.43 ± 1.22</td>
<td>&gt;1,000</td>
<td>&gt;1,000</td>
</tr>
<tr>
<td>caulibugulone B</td>
<td><img src="image2" alt="Structure" /></td>
<td>1.51 ± 0.23</td>
<td>2.72 ± 0.51</td>
<td>2.68 ± 0.23</td>
<td>130 ± 23</td>
<td>183 ± 24</td>
</tr>
<tr>
<td>caulibugulone C</td>
<td><img src="image3" alt="Structure" /></td>
<td>2.57 ± 0.60</td>
<td>5.40 ± 0.73</td>
<td>3.31 ± 0.28</td>
<td>175 ± 2</td>
<td>322 ± 32</td>
</tr>
<tr>
<td>caulibugulone D</td>
<td><img src="image4" alt="Structure" /></td>
<td>4.89 ± 0.82</td>
<td>19.1 ± 0.25</td>
<td>10.8 ± 0.46</td>
<td>&gt;1,000</td>
<td>&gt;1,000</td>
</tr>
<tr>
<td>caulibugulone E</td>
<td><img src="image5" alt="Structure" /></td>
<td>18.2 ± 1.13</td>
<td>32.5 ± 3.57</td>
<td>16.6 ± 0.98</td>
<td>&gt;1,000</td>
<td>&gt;1,000</td>
</tr>
</tbody>
</table>

$^a$ Previously reported in Wipf et al. (2004).
Figure 1
Figure 2
Figure 3

Molecular Pharmacology Fast Forward. Published on October 3, 2006 as DOI: 10.1124/mol.106.028589

32°C

39.4°C

17 h

6h, 32°C

2N 4N

2N 4N

DMSO

Nocodazole

1 μM

10 μM

30 μM

%C1: 23
%S: 67
%G2/M: 10

%C1: 1
%S: 17
%G2/M: 82

%C1: 41
%S: 29
%G2/M: 30

%C1: 1
%S: 9
%G2/M: 90

%C1: 20
%S: 22
%G2/M: 58

%C1: 9
%S: 14
%G2/M: 77

%C1: 9
%S: 15
%G2/M: 76

Caulibugulone A
Figure 4

Molecular Pharmacology Fast Forward. Published on October 3, 2006 as DOI: 10.1124/mol.106.028589

32°C

39.4°C
17 h

32°C
4–6 h

6h, 32°C

DMSO

Roscovitine

1 μM

10 μM

30 μM

Caulibugulone A
Figure 5

A

<table>
<thead>
<tr>
<th>tubulin</th>
<th>Cdc25C</th>
<th>tubulin</th>
<th>Cdc25B</th>
<th>tubulin</th>
<th>Cdc25A</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td></td>
<td>30 µM</td>
<td></td>
<td>1 µM</td>
<td></td>
</tr>
<tr>
<td>10 µM</td>
<td></td>
<td>1 µM</td>
<td></td>
<td>30 µM</td>
<td></td>
</tr>
<tr>
<td>10 µM</td>
<td></td>
<td>1 µM</td>
<td></td>
<td>30 µM</td>
<td></td>
</tr>
<tr>
<td>1 µM</td>
<td></td>
<td>1 µM</td>
<td></td>
<td>30 µM</td>
<td></td>
</tr>
</tbody>
</table>

CauI A

B

<table>
<thead>
<tr>
<th>tubulin</th>
<th>Cdc25A</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td></td>
</tr>
<tr>
<td>DA3003-1 (10 µM)</td>
<td></td>
</tr>
<tr>
<td>JUN1111 (30 µM)</td>
<td></td>
</tr>
<tr>
<td>CauI A (30 µM)</td>
<td></td>
</tr>
<tr>
<td>5169131 (30 µM)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MDA-MB-231</th>
<th>MCF7</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td></td>
</tr>
<tr>
<td>CauI A (30 µM)</td>
<td></td>
</tr>
<tr>
<td>CauI A (10 µM)</td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td></td>
</tr>
<tr>
<td>CauI A (30 µM)</td>
<td></td>
</tr>
<tr>
<td>CauI A (10 µM)</td>
<td></td>
</tr>
</tbody>
</table>
Figure 6
Figure 7